ABSTRACT
Obesity is a major public health crisis associated with high mortality rates. Previous genome-wide association studies (GWAS) investigating body mass index (BMI) have largely relied on imputed data from European individuals. This study leveraged whole-genome sequencing (WGS) data from 88,873 participants from the Trans-Omics for Precision Medicine (TOPMed) Program, of which 51% were of non-European population groups. We discovered 18 BMI-associated signals (P < 5 × 10-9). Notably, we identified and replicated a novel low frequency single nucleotide polymorphism (SNP) in MTMR3 that was common in individuals of African descent. Using a diverse study population, we further identified two novel secondary signals in known BMI loci and pinpointed two likely causal variants in the POC5 and DMD loci. Our work demonstrates the benefits of combining WGS and diverse cohorts in expanding current catalog of variants and genes confer risk for obesity, bringing us one step closer to personalized medicine.
Competing Interest Statement
DLD received grants from Bayer and honoraria from Novartis. BDHo receives grant support from Bayer and has received an honorarium from AstraZeneca for an educational lecture. CJO is employed by Novartis Institute of Biomedical Research, Cambridge MA KCB is an employee of Tempus.BMPs serve on the TOPMed Steering Committee. LMR is a consultant for the TOPMed Administrative Coordinating Center (through Westat). XLin is a consultant of AbbVie Pharmaceuticals and Verily Life Sciences.
Funding Statement
This work was funded in part by National Institutes of Health (NIH) grants (R01 DK122503, T32 HL007055, T32 HL129982, R01 HL142825, I01-BX003362, U01 HL120393, R01 HL68959, U01 HL072507, K08 HL136928, R01 HL119443, R01 HL055673-18S1, R01 HL92301, R01 HL67348, R01 NS058700, R0 AR48797, R01 DK071891, R01 AG058921, F32 HL085989, U01 HL089897, U01 HL089856, R01 HL093093, R01 HL133040, I01 BX003340, I01 BX004821, U01 HL072524,R01 HL104135-04S1, U01 HL054472, U01 HL054473, U01 HL054495, U01 HL054509, R01 HL055673 with supplement -18S1, R01 HL104608, R01AI132476, R01 AI114555, R01 HL104608-S1, U01 HL072507, P20 GM109036, KL2 TR002490 and T32 HL129982, P01 HL132825, R35 CA197449, P01 CA134294, U19 CA203654, R01 HL113338, U01 HG009088, R01 HL142302, R01 DK124097, R01 DK110113, R01 DK107786, X01 HL134588, R01 HG010297, U01 HG007416, R01 HL105756) and contracts (HHSN268201800001I, HHSN268201500014C,) American Diabetes Association (ADA) grant #1-19-PDF-045, the General Clinical Research Center of the Wake Forest University School of Medicine (M01 RR07122), and a pilot grant from the Claude Pepper Older Americans Independence Center of Wake Forest University Health Sciences (P60 AG10484). A full list of study acknowledgements is detailed in the Supplementary Note.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval by the Institutional Review Boards was obtained for each participating cohort. Informed consent was obtained from all participants, and the study was conducted in accordance with the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Published posthumously
Disclosures/Competing Interests DLD received grants from Bayer and honoraria from Novartis. BDHo receives grant support from Bayer and has received an honorarium from AstraZeneca for an educational lecture. CJO is employed by Novartis Institute of Biomedical Research, Cambridge MA KCB is an employee of Tempus. BMPs serve on the TOPMed Steering Committee. LMR is a consultant for the TOPMed Administrative Coordinating Center (through Westat). XLin is a consultant of AbbVie Pharmaceuticals and Verily Life Sciences.
Data Availability
The data used in our discovery analyses are available to applicants through dbGaP (NHLBI Trans-Omics for Precision Medicine WGS-TOPMed Data Access for the Scientific Community (https://topmed.nhlbi.nih.gov/topmed-data-access-scientific-community)).
